Cargando…

Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial

The RTS,S candidate malaria vaccine can protect against controlled human malaria infection (CHMI), but how protection is achieved remains unclear. Here, we have analyzed longitudinal peripheral blood transcriptome and immunogenicity data from a clinical efficacy trial in which healthy adults receive...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Berg, Robert A., Coccia, Margherita, Ballou, W. Ripley, Kester, Kent E., Ockenhouse, Christian F., Vekemans, Johan, Jongert, Erik, Didierlaurent, Arnaud M., van der Most, Robbert G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440508/
https://www.ncbi.nlm.nih.gov/pubmed/28588574
http://dx.doi.org/10.3389/fimmu.2017.00557
_version_ 1783238072516739072
author van den Berg, Robert A.
Coccia, Margherita
Ballou, W. Ripley
Kester, Kent E.
Ockenhouse, Christian F.
Vekemans, Johan
Jongert, Erik
Didierlaurent, Arnaud M.
van der Most, Robbert G.
author_facet van den Berg, Robert A.
Coccia, Margherita
Ballou, W. Ripley
Kester, Kent E.
Ockenhouse, Christian F.
Vekemans, Johan
Jongert, Erik
Didierlaurent, Arnaud M.
van der Most, Robbert G.
author_sort van den Berg, Robert A.
collection PubMed
description The RTS,S candidate malaria vaccine can protect against controlled human malaria infection (CHMI), but how protection is achieved remains unclear. Here, we have analyzed longitudinal peripheral blood transcriptome and immunogenicity data from a clinical efficacy trial in which healthy adults received three RTS,S doses 4 weeks apart followed by CHMI 2 weeks later. Multiway partial least squares discriminant analysis (N-PLS-DA) of transcriptome data identified 110 genes that could be used in predictive models of protection. Among the 110 genes, 42 had known immune-related functions, including 29 that were related to the NF-κB-signaling pathway and 14 to the IFN-γ-signaling pathway. Post-dose 3 serum IFN-γ concentrations were also correlated with protection; and N-PLS-DA of IFN-γ-signaling pathway transcriptome data selected almost all (44/45) of the representative genes for predictive models of protection. Hence, the identification of the NF-κB and IFN-γ pathways provides further insight into how vaccine-mediated protection may be achieved.
format Online
Article
Text
id pubmed-5440508
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54405082017-06-06 Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial van den Berg, Robert A. Coccia, Margherita Ballou, W. Ripley Kester, Kent E. Ockenhouse, Christian F. Vekemans, Johan Jongert, Erik Didierlaurent, Arnaud M. van der Most, Robbert G. Front Immunol Immunology The RTS,S candidate malaria vaccine can protect against controlled human malaria infection (CHMI), but how protection is achieved remains unclear. Here, we have analyzed longitudinal peripheral blood transcriptome and immunogenicity data from a clinical efficacy trial in which healthy adults received three RTS,S doses 4 weeks apart followed by CHMI 2 weeks later. Multiway partial least squares discriminant analysis (N-PLS-DA) of transcriptome data identified 110 genes that could be used in predictive models of protection. Among the 110 genes, 42 had known immune-related functions, including 29 that were related to the NF-κB-signaling pathway and 14 to the IFN-γ-signaling pathway. Post-dose 3 serum IFN-γ concentrations were also correlated with protection; and N-PLS-DA of IFN-γ-signaling pathway transcriptome data selected almost all (44/45) of the representative genes for predictive models of protection. Hence, the identification of the NF-κB and IFN-γ pathways provides further insight into how vaccine-mediated protection may be achieved. Frontiers Media S.A. 2017-05-23 /pmc/articles/PMC5440508/ /pubmed/28588574 http://dx.doi.org/10.3389/fimmu.2017.00557 Text en Copyright © 2017 van den Berg, Coccia, Ballou, Kester, Ockenhouse, Vekemans, Jongert, Didierlaurent and van der Most. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
van den Berg, Robert A.
Coccia, Margherita
Ballou, W. Ripley
Kester, Kent E.
Ockenhouse, Christian F.
Vekemans, Johan
Jongert, Erik
Didierlaurent, Arnaud M.
van der Most, Robbert G.
Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial
title Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial
title_full Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial
title_fullStr Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial
title_full_unstemmed Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial
title_short Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial
title_sort predicting rts,s vaccine-mediated protection from transcriptomes in a malaria-challenge clinical trial
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440508/
https://www.ncbi.nlm.nih.gov/pubmed/28588574
http://dx.doi.org/10.3389/fimmu.2017.00557
work_keys_str_mv AT vandenbergroberta predictingrtssvaccinemediatedprotectionfromtranscriptomesinamalariachallengeclinicaltrial
AT cocciamargherita predictingrtssvaccinemediatedprotectionfromtranscriptomesinamalariachallengeclinicaltrial
AT ballouwripley predictingrtssvaccinemediatedprotectionfromtranscriptomesinamalariachallengeclinicaltrial
AT kesterkente predictingrtssvaccinemediatedprotectionfromtranscriptomesinamalariachallengeclinicaltrial
AT ockenhousechristianf predictingrtssvaccinemediatedprotectionfromtranscriptomesinamalariachallengeclinicaltrial
AT vekemansjohan predictingrtssvaccinemediatedprotectionfromtranscriptomesinamalariachallengeclinicaltrial
AT jongerterik predictingrtssvaccinemediatedprotectionfromtranscriptomesinamalariachallengeclinicaltrial
AT didierlaurentarnaudm predictingrtssvaccinemediatedprotectionfromtranscriptomesinamalariachallengeclinicaltrial
AT vandermostrobbertg predictingrtssvaccinemediatedprotectionfromtranscriptomesinamalariachallengeclinicaltrial